Earnings News

Quarterly earnings reports, revenue surprises, and EPS results from top companies. Follow earnings season with analyst estimates and post-earnings stock moves.

Rocket Lab Q1 Revenue Surges 63.5% as Backlog Hits $2.2 Billion
Earnings James Calloway

Rocket Lab Q1 Revenue Surges 63.5% as Backlog Hits $2.2 Billion

Rocket Lab posted record Q1 revenue of $200.3M, narrowed its net loss, and saw backlog soar to $2.2B after a major launch deal. RKLB shares reversed a pre-report decline in after-hours trading.

RKLB
Coca-Cola Consolidated Tumbles 16% as Margin Squeeze Overshadows Sales Growth
Earnings James Calloway

Coca-Cola Consolidated Tumbles 16% as Margin Squeeze Overshadows Sales Growth

Shares of Coca-Cola Consolidated dropped 16.6% despite a 16.9% sales jump, as rising aluminum costs and tariffs squeezed margins, dragging adjusted net income down 12.3%.

COKE KO PEP KDP
Unity's AI Ad Engine Drives Revenue Growth, But Impairment Charge Weighs on Earnings
Earnings James Calloway

Unity's AI Ad Engine Drives Revenue Growth, But Impairment Charge Weighs on Earnings

Unity Software posted a 17% revenue increase in Q1 2026, fueled by its AI-powered ad engine, but a $279 million impairment charge widened its net loss to $347 million.

U
AAON Shares Surge on Record Q1, Boosted 2026 Guidance
Earnings James Calloway

AAON Shares Surge on Record Q1, Boosted 2026 Guidance

AAON reported Q1 revenue of $496.9M, up 54.3%, and backlog of $2.13B, driving a 2026 sales growth forecast of 40%-45%. Shares surged 36.2%.

AAON
Zoetis Shares Plunge 20% on Weak Pet Owner Spending, Lowered Guidance
Earnings James Calloway

Zoetis Shares Plunge 20% on Weak Pet Owner Spending, Lowered Guidance

Zoetis shares plunged 20% after cutting its 2026 outlook and missing Q1 estimates, as U.S. pet owners cut back on vet visits and premium treatments, intensifying competition.

ZTS ELAN IDXX
Duolingo Shares Jump on Q1 Beat, But Investor Focus Shifts to Bookings Slowdown
Earnings James Calloway

Duolingo Shares Jump on Q1 Beat, But Investor Focus Shifts to Bookings Slowdown

Duolingo shares rose 7.4% on strong Q1 results, but a cautious bookings forecast and heavy AI investment spending raise questions about near-term growth.

DUOL
Planet Fitness Shares Dive 31% on Slashed 2026 Guidance, Weak Membership Growth
Earnings James Calloway

Planet Fitness Shares Dive 31% on Slashed 2026 Guidance, Weak Membership Growth

Planet Fitness shares tumbled 31% after the gym chain cut its 2026 outlook, citing weak first-quarter net member adds and lower same-club sales growth of about 1%.

PLNT
Himax Technologies Stock Jumps 30% on Q2 Guidance, Dividend, and AI Glasses Push
Earnings James Calloway

Himax Technologies Stock Jumps 30% on Q2 Guidance, Dividend, and AI Glasses Push

Himax Technologies shares surged over 30% after the company forecast a Q2 rebound, declared a cash dividend, and highlighted its WiseEye AI for smart glasses and automotive chip wins.

StubHub Options Signal 13% Move Ahead of Q1 Earnings Release
Earnings James Calloway

StubHub Options Signal 13% Move Ahead of Q1 Earnings Release

Options traders anticipate a 13% swing for StubHub (STUB) ahead of its May 13 earnings report. The company faces regulatory and competitive pressures.

STUB
Symbotic Stock Dips Despite Profit as $22.7B Backlog Faces Walmart Test
Earnings James Calloway

Symbotic Stock Dips Despite Profit as $22.7B Backlog Faces Walmart Test

Symbotic shares slipped 2.3% despite posting a $9M profit and $676M revenue, as the $22.7B backlog faces heavy reliance on a single customer.

SYM WMT
Howmet Aerospace Surges on Strong Q1 Results, Lifts 2026 Outlook
Earnings James Calloway

Howmet Aerospace Surges on Strong Q1 Results, Lifts 2026 Outlook

Howmet Aerospace reported strong Q1 results, beating estimates and raising its 2026 outlook amid robust demand from commercial aerospace and defense.

HWM BA RTX GE
Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales
Earnings James Calloway

Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales

Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.

NVAX PFE SNY MRNA